Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Travere Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
TVTX
Nasdaq
2834
https://travere.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Travere Therapeutics Inc
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
- Apr 4th, 2024 8:30 pm
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
- Apr 3rd, 2024 8:30 pm
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mar 13th, 2024 9:00 pm
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
- Mar 11th, 2024 11:05 am
Travere Therapeutics to Present at Upcoming Investor Conferences
- Feb 26th, 2024 9:30 pm
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
- Feb 23rd, 2024 12:05 pm
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
- Feb 23rd, 2024 7:00 am
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Feb 15th, 2024 9:01 pm
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
- Feb 8th, 2024 9:30 pm
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
- Feb 1st, 2024 9:30 pm
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
- Jan 25th, 2024 9:05 pm
Travere Therapeutics Provides Corporate Update and 2024 Outlook
- Jan 8th, 2024 12:00 pm
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 2nd, 2024 9:30 pm
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
- Dec 14th, 2023 12:30 pm
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
- Dec 4th, 2023 9:05 pm
Travere Therapeutics (NASDAQ:TVTX) shareholders have endured a 74% loss from investing in the stock three years ago
- Dec 3rd, 2023 12:49 pm
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
- Nov 21st, 2023 9:30 pm
Travere Therapeutics Reports Third Quarter 2023 Financial Results
- Nov 7th, 2023 9:01 pm
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
- Nov 3rd, 2023 2:46 pm
Travere Therapeutics to Report Third Quarter 2023 Financial Results
- Oct 24th, 2023 8:30 pm
Scroll